Please note, the 3rd TReg Directed Therapies 2020 Summit is still going ahead as planned in Boston, USA this July 28-30, 2020 in line with current guidance from the Center for Disease Control and Prevention (CDC) and the World Health Organization (WHO).
Hanson Wade is continuing to monitor and assess developments with COVID-19, and as the health and well-being of our customers is of utmost importance to us, are taking extra measures to ensure we make the right decisions for this meeting.
For a full update, please see our COVID-19 update here.
The 3rd Treg Directed Therapies Summit returns to bring you the leaders from key pharma, biotech, academia and service and solution providers to discuss how to target and translate Treg modifying therapies with enhanced persistence and durability.
Over 100 of the world’s leading experts will come together to explore fundamental Treg cell biology, discover pioneering Treg cell engineering techniques and discuss how to translate effective and safe Treg directed therapies through the clinic.
Join us, and the leading experts from Quell Therapeutics, Pandion Therapeutics, AZTherapies and AnTolRx as we drive towards approved Treg directed therapies.
The therapeutic potential of Treg cells has been demonstrated in various preclinical models of numerous indications such as multiple sclerosis, type 1 diabetes mellitus and graft-versus-host disease. Consequently, the development of adoptive cell therapy and other approaches to direct Treg cells, such as low dose IL-2, tolerogenic nanoparticles and pharmacological approaches, has advanced in the clinic.